| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 07/29/2004 | WO2004063336A2 Uses of deazapurines for the treatment of reperfusion injuries, osteoporosis and/or bone metastasis |
| 07/29/2004 | WO2004063217A1 Dimerized peptide |
| 07/29/2004 | WO2004063202A1 Fused furan compound |
| 07/29/2004 | WO2004063181A1 Urea derivatives and their use as anti-inflammatory agents |
| 07/29/2004 | WO2004062686A2 Therapeutic use of modulators of notch |
| 07/29/2004 | WO2004062683A1 Improvements in or relating to immune functions |
| 07/29/2004 | WO2004062664A1 Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders |
| 07/29/2004 | WO2004062657A1 Acylated 4-amidino- and 4-guanidinobenzylamines for the inhibition of plasma kallikrein |
| 07/29/2004 | WO2004062653A2 The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis |
| 07/29/2004 | WO2004062619A2 SOLUBLE FcϜR FUSION PROTEINS AND METHODS OF USE THEREOF |
| 07/29/2004 | WO2004062551A2 RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN |
| 07/29/2004 | WO2004050086A8 Derivatives of indole-3-carboxamide, preparation method thereof and application of same in therapeutics |
| 07/29/2004 | WO2004015057A9 Mucin-immunoglobulin fusion proteins |
| 07/29/2004 | WO2004014913A3 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| 07/29/2004 | WO2003105811A3 Controlled release compositions and methods for using same |
| 07/29/2004 | WO2003094861A3 Bis-benzimidazoles and related compounds as potassium channel modulators |
| 07/29/2004 | WO2003094850A3 Lipid a and other carbohydrate ligand analogs |
| 07/29/2004 | WO2003086317A3 Protein a compositions and methods of use |
| 07/29/2004 | WO2003075741A3 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE |
| 07/29/2004 | WO2003068803A3 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| 07/29/2004 | WO2003028634A8 Method of treatment using ligand-immunogen conjugates |
| 07/29/2004 | WO2003022123A3 Methods of kidney transplantation utilizing developing nephric tissue |
| 07/29/2004 | US20040147745 Novel compounds and compositions as protease inhibitors |
| 07/29/2004 | US20040147741 Heptadecapeptide nociceptin opioid receptor modulators; pain relievers; synthesis |
| 07/29/2004 | US20040147739 Novel anti-infectives |
| 07/29/2004 | US20040147724 for diagnosis/treatment of cancer, myeloproliferative disorders, angiogenesis, obesity, osteoporosis, non-insulin dependent diabetes, lipid metabolism disorder, hypercalcemia, hypercholestrolemia; genetic engineering |
| 07/29/2004 | US20040147714 High linear content; low molecular weight, narrow range; using alkali metal secondary amine polymerization aide |
| 07/29/2004 | US20040147591 Viricides; anticancer agents; immunostimulant |
| 07/29/2004 | US20040147587 Compounds for the modulation of the glycolysis enzyme and/or transaminase complex |
| 07/29/2004 | US20040147586 Antiproliferative agents; anticancer agents; glioblastomas; antidiabetic agents; autoimmune disorders; skin disorders; antiarthritic agents; antiinflammatory agents; cardiovascular disorders |
| 07/29/2004 | US20040147578 Use of lipoaminoacids as absorption promoters in a pharmaceutical composition |
| 07/29/2004 | US20040147577 Heterocyclic compounds |
| 07/29/2004 | US20040147573 Metalloproteinase inhibitors |
| 07/29/2004 | US20040147570 Substituted 1 and 2-naphthol mannich bases |
| 07/29/2004 | US20040147562 Controlling cell gene expression; moderate cell proliferation; anticancer agents; antiinflammatory agents; cardiovascular disorders; autoimmune disease |
| 07/29/2004 | US20040147558 Synthesis of 3-amino-thalidomide and its enantiomers |
| 07/29/2004 | US20040147556 Analgesics; anxiolytuic agents; gastrointestinal disorders |
| 07/29/2004 | US20040147553 Efficiency; side effect reduction; antiarthriutic agents; autoimmune diseases |
| 07/29/2004 | US20040147546 Heterocyclic compounds |
| 07/29/2004 | US20040147542 Chemical compounds |
| 07/29/2004 | US20040147525 Antiinflammatory agents; analgesics; antiarthritic agents |
| 07/29/2004 | US20040147516 Blocking interleukins; antiinflammatory agents; autoimmune diseases ; antiarthritic agents; osteoporosis |
| 07/29/2004 | US20040147512 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/29/2004 | US20040147490 Immunosuppressants |
| 07/29/2004 | US20040147472 Antisense modulation of transforming growth factor beta receptor II expression |
| 07/29/2004 | US20040147468 Immunostimulatory nucleic acid molecules |
| 07/29/2004 | US20040147010 Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative, potential pathogenic gram-positive bacteria |
| 07/29/2004 | US20040147003 Comprises nucleotide sequences coding kinase for use as tool in identifying modulators for treatment and prevention cell proliferative disorders |
| 07/29/2004 | US20040146991 Identifying modulator of activation inducible lymphocyte immunomodulatory molecule (AILIM) for use in suppressing, preventing and/or treating inflammatory, autoimmune and allergic disorders |
| 07/29/2004 | US20040146981 DNA encoding human serine protease D-G |
| 07/29/2004 | US20040146967 Novel g protein-coupled receptor protein and dna thereof |
| 07/29/2004 | US20040146964 Assays, methods and means |
| 07/29/2004 | US20040146948 single-chain variable region fragment (scFv) comprising a heavy chain variable region (VH) operably linked to a light chain variable region (VL); for cancer treatment |
| 07/29/2004 | US20040146925 for diagnosis and targeted drug delivery for blood cancer and monitoring protein expression or activity of white blood cells in vitro |
| 07/29/2004 | US20040146853 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 07/29/2004 | US20040146520 Materials and methods relating to immune suppression |
| 07/29/2004 | US20040146515 Chemically programmable immunity |
| 07/29/2004 | US20040146513 Monoclonal antibodies against human protein Mcm3, process for their production, and their use |
| 07/29/2004 | US20040146506 Antibodies specific for a cell surface molecule mediating cell adhesion and signal transmission, cells secreting such antibodies, and methods of making and using such antibodies |
| 07/29/2004 | US20040146505 Polypeptide comprising portion with part of human fc fragment which binds to CD64 antigen, and portion comprising heterologous T cell epitopes; antitumor and anticarcinogenic agents |
| 07/29/2004 | US20040146504 Anti-IgE vaccines |
| 07/29/2004 | DE10303671A1 New 8alpha,14beta-dialkyl-18-nor steroids useful as pharmaceuticals, intermediates or carriers for treating e.g. tumors, alzheimers disease |
| 07/29/2004 | DE10301300A1 Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein Use of acylated 4-amidino and 4-Guanidinobenzylaminen for the inhibition of plasma kallikrein |
| 07/29/2004 | CA2513701A1 Dimerized peptide |
| 07/29/2004 | CA2512974A1 Soluble fc.gamma.r fusion proteins and methods of use thereof |
| 07/29/2004 | CA2512545A1 Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf) |
| 07/29/2004 | CA2512021A1 The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis |
| 07/29/2004 | CA2511818A1 Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders |
| 07/28/2004 | EP1440982A2 Ifn-thy fusion protein, dna coding therefore, its preparation and application |
| 07/28/2004 | EP1440980A2 Peptide analogs of human myelin basic protein |
| 07/28/2004 | EP1440976A1 Modified aminoacids, pharmaceuticals containing these compounds and method for their production |
| 07/28/2004 | EP1440973A2 Epothilone derivatives, preparation and use |
| 07/28/2004 | EP1440688A1 Peroxisome proliferator activated receptor ligands and process for producing the same |
| 07/28/2004 | EP1440161A2 7118, a human arginine n-methyltransferase family member and uses therefor |
| 07/28/2004 | EP1440157A1 Methods and means for producing proteins with predetermined post-translational modifications |
| 07/28/2004 | EP1440083A2 Molecules |
| 07/28/2004 | EP1440073A1 Pde9 inhibitors for treating cardiovascular disorders |
| 07/28/2004 | EP1440072A2 Purine analogs having hsp90-inhibiting activity |
| 07/28/2004 | EP1440062A1 An efficient synthesis of 5-heteroatom-containing-pyrazoles |
| 07/28/2004 | EP1440059A1 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists |
| 07/28/2004 | EP1440057A1 Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
| 07/28/2004 | EP1439850A1 Soluble proteins that inhibit cytokine signal transduction pathways |
| 07/28/2004 | EP1439842A1 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
| 07/28/2004 | EP1439838A1 Macrolides containing pharmaceutical compositions |
| 07/28/2004 | EP1439837A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors |
| 07/28/2004 | EP1439833A1 Combination of liponic acid and glutamine in food and pharmaceutical products |
| 07/28/2004 | EP1238095A4 Compositions and methods for caspase-induced apoptosis |
| 07/28/2004 | EP1226244B1 Polypeptides with non-natural primary signalling motifs |
| 07/28/2004 | EP1175445B1 Specific antibodies and antibody fragments for tgfbeta1 |
| 07/28/2004 | EP0983286B1 Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| 07/28/2004 | EP0935607B1 Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor |
| 07/28/2004 | EP0927183B1 Spirocyclic metalloprotease inhibitors |
| 07/28/2004 | EP0912741B1 T-cell selective interleukin-4 agonists |
| 07/28/2004 | EP0823895B1 Fatty acid esters as bioactive compounds |
| 07/28/2004 | EP0752884B1 Method of treating auto-immune diseases using type one interferons |
| 07/28/2004 | CN1516739A Use of HMG fragments as anti-inflammatory agents |
| 07/28/2004 | CN1516700A Substituted 4H-chromenes and analogs as activators ofgasp ases and inducers of apoptosis and use thereof |
| 07/28/2004 | CN1516698A Arylindenopyridines with PDE inhibiting activity |
| 07/28/2004 | CN1516691A Phenylpyridine carbonyl piperazine derivative |
| 07/28/2004 | CN1516690A Heterocyclic derivatives and medicines |